ArticleHuman genetics2012
Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes.
Article in Human genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- From genes to treatments: a systematic review of the pharmacogenetics in smoking cessation.Pharmacogenomics · 2018Pooled it
- Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects.The pharmacogenomics journal · 2013Pooled it
- Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.Drug and alcohol dependence · 2015Trial
- Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion.Addiction (Abingdon, England) · 2013Trial
- Pharmacogenetic smoking cessation intervention in a health care setting: a pilot feasibility study.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2013Trial
- Structure-activity relationships andz interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm.The Journal of international medical research · 2023Review
- Genomic medicine to reduce tobacco and related disorders: Translation to precision prevention and treatment.Addiction neuroscience · 2023Article
- Association of PolymorphismInternational journal of environmental research and public health · 2022Article
- Rodent models for nicotine withdrawal.Journal of psychopharmacology (Oxford, England) · 2021Review
- Association of NRG3 and ERBB4 gene polymorphism with nicotine dependence in Turkish population.Molecular biology reports · 2021Article
- The effect of genetic variations in the choline acetyltransferase gene (ChAT) on waterpipe tobacco smoking dependence.Tobacco induced diseases · 2020Article
- Chronic Obstructive Pulmonary Disease Risk and Smoking Cessation Changes Induced byBalkan journal of medical genetics : BJMG · 2019Article
- Pathways to precision medicine in smoking cessation treatments.Neuroscience letters · 2018Review
- Leveraging Genomic Data in Smoking Cessation Trials in the Era of Precision Medicine: Why and How.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2018Review
- Neuregulin signaling pathway in smoking behavior.Translational psychiatry · 2017Article
- Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men.Behavioral and brain functions : BBF · 2017Article
- Prenatal fat exposure and hypothalamic PPAR β/δ: Possible relationship to increased neurogenesis of orexigenic peptide neurons.Peptides · 2016Article
- The Sociopharmacology of Tobacco Addiction: Implications for Understanding Health Disparities.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2016Review
- Nicotine withdrawal.Current topics in behavioral neurosciences · 2015Review
- Structure-function elucidation of a new α-conotoxin, Lo1a, from Conus longurionis.The Journal of biological chemistry · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Many smokers attempt to quit smoking but few are successful in the long term. The heritability of nicotine addiction and smoking relapse have been documented, and research is focused on identifying specific genetic influences on the ability to quit smoking and response to specific medications. Research in genetically modified cell lines and mice has identified nicotine acetylcholine receptor subtypes that mediate the pharmacological and behavioral effects of nicotine sensitivity and withdrawal. Human genetic association studies have identified single nucleotide polymorphisms (SNPs) in genes encoding nicotine acetylcholine receptor subunits and nicotine metabolizing enzymes that influence smoking cessation phenotypes. There is initial promising evidence for a role in smoking cessation for SNPs in the β2 and α5/α3/β4 nAChR subunit genes; however, effects are small and not consistently replicated. There are reproducible and clinically significant associations of genotypic and phenotypic measures of CYP2A6 enzyme activity and nicotine metabolic rate with smoking cessation as well as response to nicotine replacement therapies and bupropion. Prospective clinical trials to identify associations of genetic variants and gene-gene interactions on smoking cessation are needed to generate the evidence base for both medication development and targeted therapy approaches based on genotype.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.